How many people filled a new GLP-1 prescription?
In one integrated U.S. health system, 726 of 2,435 patients (29.8%) with a new GLP-1 prescription from 2012 through 2019 had no documented pharmacy fill for a drug in that class within 30 days. That means 70.2% had a documented fill. The records could miss a fill paid in cash outside the health plan [1].
A Colorado study linked records for 9,848 orders and 6,094 patients enrolled in Medicare or commercial insurance between 2018 and 2022. Within 90 days, 60.1% of the orders had a recorded fill. That study counted initial orders and refill orders, and the rate varied by indication: 37.2% for obesity alone, 47.5% for diabetes alone and 64.6% for both [2]. Those figures describe the cohort. The GLP-1 insurance coverage guide explains how coverage rules can vary by diagnosis and plan.
What happens after an insurance denial?
The steps in GLP-1 prior authorization can affect when a pharmacy can bill a plan. In separate national claims data from 2018 through 2024, 34.1% of 173,782 people with a first observed denied claim and enough follow-up had a paid GLP-1 fill within 90 days. The data did not identify whether each denial reflected prior authorization, a formulary exclusion, step therapy or another reason [3].
In the 2022 Medical Expenditure Panel Survey, adults with type 2 diabetes and above-median income had higher odds of semaglutide use (OR 1.61, 95% CI 1.14 to 2.26). Private insurance was also associated with higher odds (OR 1.52, 95% CI 1.04 to 2.22). The survey measured use, so it cannot tell us the share of written prescriptions people filled [5].
What a two-drug trial adds
The PRECIDENTD feasibility report followed 173 adults with type 2 diabetes and cardiovascular disease or elevated cardiovascular risk. Nearly all had insurance. Participants were randomized to a GLP-1 receptor agonist, an SGLT2 inhibitor, or both. Within four months, 84% of those assigned either single drug reported obtaining it, compared with 53% assigned both who reported obtaining both. During median follow-up of ten months, those figures reached 87% and 68% [4].
Among those who obtained all assigned study medicines, 22% in the pooled single-drug group and 49% in the two-drug group stopped at least one, most often because of side effects. The study pooled two different single-drug groups and included participants already taking a GLP-1 at enrollment. It did not estimate a general first-fill rate for GLP-1 medicines or report the main trial’s long-term cardiovascular and kidney outcomes [4].
What happens after the first fill?
Studies measuring how long people stay on a GLP-1 start counting after the first fill. In one Kaiser Permanente Colorado cohort, 436 of 1,374 adults (31.7%) who first filled semaglutide or liraglutide between 2018 and 2023 stopped within 180 days. Among those who stopped, an adverse drug reaction was documented for 26.8% and a cost concern for 14.4%. The adjusted odds of stopping were higher for those with overweight or obesity alone than for those with both diabetes and overweight or obesity (OR 2.46, 95% CI 1.17 to 5.17) [6].
If cost affects whether you fill or refill, the guide to monthly GLP-1 costs explains which charges to confirm with the pharmacy or plan before comparing the first fill with later refills.